Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically proven advanced cancer not curable by standard chemotherapy,
radiotherapy, or surgery

- Clinical evidence of primary lung or tracheal cancer OR

- Metastatic cancer to the lung

- Extrathoracic metastases eligible if following criteria are met:

- Sites are stable

- Pulmonary sites are primary life-threatening sites

- Evidence that study treatment may benefit the patient

- Measurable or evaluable disease

- No germ cell tumor, leukemia, or lymphoma involving the lungs that is treatable with
systemic agents

- No complete atelectasis due to high-grade airway obstruction

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- ECOG 0-1

Life expectancy:

- More than 3 months

Hematopoietic:

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 10 g/dL

Hepatic:

- Bilirubin no greater than 1.0 mg/dL

- AST and ALT less than 1.5 times upper limit of normal

Renal:

- Creatinine no greater than 1.6 mg/dL OR

- Creatinine clearance at least 60 mL/min

Cardiovascular:

- LVEF at least 40% by MUGA scan or echocardiogram

- No unstable angina, congestive heart failure, or symptomatic arrhythmias

Pulmonary:

- DLCO at least 50% predicted

- FVC and FEV1 at least 50% predicted

- Resting oxygen saturation at least 90%

- Exercise oxygen saturation at least 85%

- Oxygen consumption greater than 50% predicted

- No prior radiation pneumonitis

- No asthma

- No radiation-induced pulmonary damage

Other:

- No hypersensitivity to doxorubicin

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after study

- HIV negative

- No congenital problems (e.g., cleft palate) or other anomalies that prevent tight fit
of a mouthseal

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- At least 4 weeks since prior biologic therapy and recovered

- No prior trastuzumab (Herceptin)

Chemotherapy:

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy and recovered

- Prior doxorubicin allowed if LVEF at least 40% by MUGA scan or echocardiogram

- No prior mitomycin, bleomycin, or nitrosoureas

- No other concurrent systemic chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- See Disease Characteristics

- At least 4 weeks since prior radiotherapy and recovered

- At least 12 months since prior radiotherapy to chest

- No prior radiotherapy to more than 20% of total lung volume

- Prior chest wall or primary breast radiotherapy allowed

- Prior radioactive iodine allowed

- No concurrent thoracic radiotherapy

Surgery:

- See Disease Characteristics

- No prior total pneumonectomy

Other:

- No other concurrent experimental drug